摘要
目的 系统评价缬沙坦氨氯地平片（倍博特）治疗高血压的有效性和安全性。方法 采用循证医学的方法,将国内外符合纳入标准的12项（共计2 796例患者）关于倍博特治疗高血压的随机对照试验进行Meta分析。采用收缩压、舒张压、24 h平均血压、临床疗效以及不良反应率作为结局指标判定治疗效果。运用Rev Man 5.0软件进行Meta分析。结果 Meta分析结果显示倍博特的临床疗效优于氨氯地平组（OR=3.36,95%CI：2.17~5.19,P〈0.001）、缬沙坦80 mg组（OR=3.19,95%CI：2.40~4.24,P〈0.001）和缬沙坦160 mg组（OR=1.61,95%CI：1.12~2.32,P=0.010）;倍博特组患者不良反应的发生率低于氨氯地平组（OR=0.45,95%CI：0.27~0.74,P〈0.001）,而倍博特组与缬沙坦80 mg组及160 mg组不良反应的发生率差异无统计学意义。结论 倍博特治疗高血压的效果优于对照组,且具有较好的安全性。
Objective To review effectiveness and safety of valsartan-amlodipine tablet for hypertension. Methods According to evidence-based medicine criteria, 12 randomized controlled trials （including 2 796 patients ） focusing on Valsartan-amlodipine tablet for the treatment of hypertension were included to perform a meta-analysis. Treatment effects were assessed using systolic blood pressures, diastolic blood pressures, the average blood pressure over 24h, clinical effects and the incidence of adverse reactions. All data were analyzed by using Review Manager 5.0. Results Meta-analysis re- sults indicated that Valsartan-amlodipine tablet group had better clinical efficacy than amlodipine group （ OR = 3.36,95% CI：2. 17 ~ 5.19,P 〈 0. 001 ）, va｜sartan （80 mg） group （ OR = 3.19,95% CI：2.40 ~ 4.24, P 〈 0. 001 ）, and valsartan （160 mg） group （OR = 1.61,95% CI：I. 12 -2,32,P = 0. 010）. Compared with amlodipine group, the incidence of ad- verse reactions in valsartan-amlodipine tablet group was lower （ OR = 0.45,95% CI：O. 27 - 0. 74 ,P 〈 0. 001 ） , but there was no significant difference in the incidence of adverse reactions between valsartan-amlodipine tablet group and valsartan group. Conclusions Valsartan-amlodipine tablet for the treatment of hypertension is safe and effective.
出处
《中华疾病控制杂志》
CAS
CSCD
北大核心
2015年第1期82-85,共4页
Chinese Journal of Disease Control & Prevention
基金
安徽省卫生厅科技项目(13FR028)
